Get the Daily Brief
Latest Biotech News
Company M&A: Medtronic expands neuromodulation reach with SPR Therapeutics deal
Medtronic agreed to acquire SPR Therapeutics for $650 million, marking the company’s third major acquisition in 2026. The deal targets growth in neuromodulation and pain intervention, adding SPR’s...
Deck-to-bedside device innovation: wearable ultrasound for continuous high-risk pregnancy monitoring
Engineers at the University of California San Diego unveiled a wearable ultrasound patch designed for continuous fetal monitoring throughout pregnancy, aiming to reduce reliance on intermittent...
PROTAC milestone: first FDA-approved PROTAC therapy enters clinical oncology
Vepdegestrant (Veppanu) is now the first FDA-approved PROTAC therapy, according to the provided report, marking a regulatory milestone for targeted protein degradation in oncology. Developed as a...
Oncology biology: NUP62 silencing reverses osimertinib resistance in EGFR-mutant lung cancer
Researchers reported that NUP62 silencing can reverse resistance to osimertinib in non-small cell lung cancer models, aiming at a core mechanism behind failure of third-generation EGFR-TKIs. The...
Dealmaking and funding: Accro Bioscience raises $50 million for oral immune-mediated pipeline
Accro Bioscience closed a $50 million Series C financing round to advance an oral immune-mediated disease pipeline, according to the provided report. The round was led by OrbiMed with...
AI in biotech operations: BigHat CEO pushes back on speed-only claims for drug design
BigHat Biosciences CEO Peyton Greenside criticized hype around AI drug discovery, arguing that demonstrations showing rapid molecule design miss the downstream work required to make therapies. In...
AI-driven manufacturing analytics: lab automation adds power-savings and smarter droplet performance
Beckman Coulter Life Sciences released the Echo 650 Plus Series acoustic liquid handler, touting reduced operating costs, lower power consumption, and enhanced system intelligence for...
Biopharma R&D scale-up: evidence review tackles bottlenecks in process intensification
A report on process intensification highlights persistent misconceptions that can slow adoption of advanced manufacturing and development workflows. The piece—citing a survey of more than 150 life...
Alzheimer’s deal option in Fosun’s Asia push
Fosun Pharma has paid $60 million upfront to secure an exclusive global option on AR1001, an oral Alzheimer’s candidate from South Korea’s AriBio. The agreement gives Fosun development,...
Accro Bioscience raises fresh Series C to expand oral immune pipeline
Suzhou-based Accro Bioscience closed a $50 million Series C financing led by OrbiMed, funding continued development of its oral immune-mediated disease pipeline. The round also included...
FDA accelerates first BCL2 inhibitor approval for mantle cell lymphoma
The FDA granted accelerated approval to Beqalzi (sonrotoclax), becoming the first BCL2 inhibitor approved specifically for relapsed or refractory mantle cell lymphoma after at least two prior...
Lilly spotlights early gene-editing effect on cholesterol with Verve asset
Eli Lilly said its high dose of VERV-102, a gene-editing therapy acquired through its $1 billion buyout of Verve Therapeutics, reduced cholesterol by 62% in participants in an early-phase clinical...
PROTAC landmark: vepdegestrant becomes FDA-approved CRBN-recruiting therapy
Vepdegestrant (Veppanu®; ARV-471), an oral CRBN-recruiting PROTAC, became the first FDA-approved PROTAC therapy as of May 2026, marking a regulatory milestone for targeted protein degradation in...
AI CEO pushes back on drug-design hype while citing collaboration momentum
BigHat Biosciences CEO Peyton Greenside challenged parts of the AI drug-development narrative, arguing that speed demos obscure the downstream experimental work needed to make medicines. Greenside...
FDA leadership profile highlights shifting oversight expectations
STAT+ profiled Kyle Diamantas’ rise to lead the FDA’s top food role in 2025, noting that the appointment came from outside traditional public health and scientific leadership. The piece describes...
Regulatory-quality playbook: myths around process intensification
A survey-based report on process intensification highlighted four common misconceptions that may be slowing manufacturing improvements across life sciences. The piece argues that teams should...
Clinical research: NUP62 silencing targets osimertinib resistance in lung cancer
Researchers reported a strategy to reverse osimertinib resistance in non-small cell lung cancer by silencing NUP62. The approach targets resistance in patients whose tumors evolve beyond the...
Durable maintenance in ES-SCLC: durvalumab plus anlotinib outperforms monotherapy
A multicenter randomized Phase 2 DURABLE trial reported improved outcomes for extensive-stage small-cell lung cancer with a maintenance regimen combining durvalumab and anlotinib versus durvalumab...
FDA approvals for oncology—first-in-class BCL2 inhibition in mantle cell lymphoma
The FDA granted accelerated approval to BeOne Medicines’ sonrotoclax (Beqalzi), the first BCL2 inhibitor specifically indicated for adults with relapsed or refractory mantle cell lymphoma (MCL)...
Gene editing for cardiovascular risk—early LDL reduction from Lilly/Verve
Eli Lilly reported early phase 1 clinical data for its gene-editing therapy VERV-102, acquired from Verve Therapeutics in a $1 billion deal, showing a 62% cholesterol reduction at a high dose in...